Your browser doesn't support javascript.
loading
Immunotherapy in Breast Cancer: the New Frontier.
Hu, Zishuo I; McArthur, Heather L.
Afiliação
  • Hu ZI; 1Mount Sinai Health System, Icahn School of Medicine, New York, NY USA.
  • McArthur HL; 2Department of Medicine, Breast Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, 1S35, Los Angeles, CA 90048 USA.
Curr Breast Cancer Rep ; 10(2): 35-40, 2018.
Article em En | MEDLINE | ID: mdl-29881518
ABSTRACT
PURPOSE OF REVIEW This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT

FINDINGS:

Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients.

SUMMARY:

Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article